| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1367349 | Bioorganic & Medicinal Chemistry Letters | 2006 | 7 Pages |
Abstract
The identification of an MCH R1 antagonist screening hit led to the optimization of a class of benzimidazole-based MCH R1 antagonists. Structure–activity relationships and efforts to optimize pharmacokinetic properties are detailed along with the demonstration of the effectiveness of an MCH R1 antagonist in an animal model of obesity.
Graphical abstractStructure–activity relationships and efforts to optimize pharmacokinetic properties of a class of benzimidazole-based MCH R1 antagonists are described.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Andrew J. Carpenter, Kamal A. Al-Barazanji, Kevin K. Barvian, Michael J. Bishop, Christy S. Britt, Joel P. Cooper, Aaron S. Goetz, Mary K. Grizzle, Donald L. Hertzog, Diane M. Ignar, Ronda O. Morgan, Gregory E. Peckham, Jason D. Speake, Will R. Swain,